Free Trial
→ Expert Alert: Massive Bubble Could Crash Your Wealth (From American Alternative) (Ad)tc pixel

Nanobiotix (NASDAQ:NBTX) Trading Down 5.2% - Here's Why

Written by MarketBeat
Updated August 26, 2025
Nanobiotix logo with Medical background

Key Points

  • Nanobiotix's stock experienced a decline of 5.2%, trading at $8.53, down from a previous close of $9.00, with a notable trading volume increase of 47%.
  • Institutional investors and hedge funds currently own 38.81% of Nanobiotix's stock, with new positions acquired by firms like Geode Capital and Jane Street Group.
  • The company is focused on developing nanotechnology-based treatments for various cancers, with its lead product candidate being NBTXR3.
  • Five stocks to consider instead of Nanobiotix.

Nanobiotix S.A. Sponsored ADR (NASDAQ:NBTX - Get Free Report) shares fell 5.2% on Wednesday . The stock traded as low as $8.20 and last traded at $8.53. 19,089 shares were traded during mid-day trading, an increase of 47% from the average session volume of 13,015 shares. The stock had previously closed at $9.00.

Nanobiotix Price Performance

The firm's 50-day moving average price is $6.28 and its two-hundred day moving average price is $4.60.

Institutional Investors Weigh In On Nanobiotix

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Geode Capital Management LLC purchased a new stake in Nanobiotix during the fourth quarter valued at approximately $29,000. Millennium Management LLC purchased a new stake in Nanobiotix during the fourth quarter valued at approximately $39,000. Finally, Jane Street Group LLC purchased a new stake in Nanobiotix during the fourth quarter valued at approximately $73,000. Hedge funds and other institutional investors own 38.81% of the company's stock.

Nanobiotix Company Profile

(Get Free Report)

Nanobiotix SA, a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.

Featured Stories

Should You Invest $1,000 in Nanobiotix Right Now?

Before you consider Nanobiotix, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nanobiotix wasn't on the list.

While Nanobiotix currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Analysts Agree—These Gold Picks Outshine the Rest Cover
Analysts Agree—These Gold Picks Outshine the Rest

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report
Like this article? Share it with a colleague.